600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.
Closed 02-27 15:00:00
26.48
-0.03
-0.11%
High26.60Low26.42Vol12.62M
Open26.51D1 Closing26.51Amplitude0.68%
Mkt Cap70.70BTradable Cap56.08BTotal Shares2.67B
T/O334.00MT/O Rate0.60%Tradable Shares2.12B
P/B1.47ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held shareholder meetings
Reuters  ·  02-27 22:08
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held shareholder meetings
Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue
MT Newswires Live  ·  02-26 20:42
Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue
FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors
Stock News  ·  02-26 18:40
FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors
Shanghai Fosun Pharmaceutical Says It Received Securities Regulator's Approval to Issue up to 6 Bln Yuan of Bonds
THOMSON REUTERS  ·  02-26 17:33
Shanghai Fosun Pharmaceutical Says It Received Securities Regulator's Approval to Issue up to 6 Bln Yuan of Bonds
BRIEF-Shanghai Fosun Pharmaceutical Receives Regulatory Approval For Bond Issuance
Reuters  ·  02-26 17:33
BRIEF-Shanghai Fosun Pharmaceutical Receives Regulatory Approval For Bond Issuance
Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China
MT Newswires Live  ·  02-25 20:23
Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China
Shanghai Fosun Pharma - Units Gets Approval From Nmpa for Clinical Trial of Luvometinib Tablets in Combination With Anlotinib
THOMSON REUTERS  ·  02-25 17:44
Shanghai Fosun Pharma - Units Gets Approval From Nmpa for Clinical Trial of Luvometinib Tablets in Combination With Anlotinib
Fosun Pharma Industrial Wins NMPA Approval for Luvometinib Combo Phase II NSCLC Trial
Reuters  ·  02-25 17:43
Fosun Pharma Industrial Wins NMPA Approval for Luvometinib Combo Phase II NSCLC Trial
Fosun Pharmaceutical Amends Drug Licensing Agreements
MT Newswires Live  ·  02-25
Fosun Pharmaceutical Amends Drug Licensing Agreements
Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application
MT Newswires Live  ·  02-13
Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application
FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review
Stock News  ·  02-13
FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review
Shanghai Fosun Pharma - Drug Registration Application of Moxetomidate Hydrochloride Injection Accepted by Nmpa
THOMSON REUTERS  ·  02-13
Shanghai Fosun Pharma - Drug Registration Application of Moxetomidate Hydrochloride Injection Accepted by Nmpa
Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted
Reuters  ·  02-13
Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted
Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial
MT Newswires Live  ·  02-13
Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial
Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic
MT Newswires Live  ·  02-10
Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic
BRIEF-Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA
Reuters  ·  02-10
BRIEF-Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA
Shanghai Fosun Pharma - Drug Registration Application of Tetracaine Hydrochloride Gel Accepted by China's Nmpa
THOMSON REUTERS  ·  02-10
Shanghai Fosun Pharma - Drug Registration Application of Tetracaine Hydrochloride Gel Accepted by China's Nmpa
Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted
Reuters  ·  02-10
Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted
FOSUN PHARMA's Cyclophosphamide Injection Application Accepted for Review
Stock News  ·  02-05
FOSUN PHARMA's Cyclophosphamide Injection Application Accepted for Review
Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted
Reuters  ·  02-05
Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted

Introduction

Company Name.
上海复星医药(集团)股份有限公司
Industry:
医药制造业
Listing Date:
1998-08-07
Main Business:
　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
Issue price:
7.15